In addition to IMGN901 and IMGN388, we have a number of earlier-stage compounds in our preclinical pipeline. We expect to start unveiling our most advanced ones in 2010.

Other product candidates – besides T-DM1 and SAR3419 – are in development through our collaborations. Two other TAP compounds are in clinical testing:

• BT-062 – Our collaborator Biotest is developing this TAP compound for the treatment of multiple myeloma. BT-062 began Phase I testing in mid-2008. The first clinical data were presented at a medical meeting in December 2009. ImmunoGen has certain opt-in rights for the US.

• BIIB015 – Our collaborator Biogen Idec is developing this Cripto-targeting TAP compound for the treatment of solid tumors. BIIB015 also entered Phase I testing in mid-2008.

Information on other potential collaboration compounds that has been disclosed includes:

• Two additional compounds – SAR566658 and SAR650984 – have been disclosed in our collaboration with sanofi-aventis. SAR566658 is a TAP compound for the treatment of breast and ovarian cancers and other solid tumors, and SAR650984 is a naked antibody for hematological malignancies.



• In October 2008, Bayer HealthCare licensed rights to use our TAP technology to a target found on solid tumors.



• Genentech has taken exclusive licenses to use our TAP technology with therapeutic antibodies to four undisclosed targets in addition to their license for HER2. The most recent license was taken in December 2008.


• In September 2009, Amgen Inc. licensed rights to use our TAP technology for an undisclosed target.

Back to Pipeline